drugset / Trial / NCT00681824

Fibrin Sealant for the Sealing of Dura Sutures

NCT00681824 ↗

Phase 2 Completed 95 enrolled Baxter Healthcare Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of FS VH S/D 500 s-apr, a double virus-inactivated biological two-component fibrin sealant, for use in posterior fossa surgery as an adjunct to dura and dura substitute sutures in preventing postoperative cerebrospinal fluid (CSF) leakage.

Timeline

Start
2008-05
Primary completion
2010-03
Completion
2010-03

Outcome

Missed primary endpoint

registry p = 0.7159; likelihood ratio of chi squared test NCT00681824 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject FS VH S/D 500 s-apr Protein / enzyme biologic — Topical